FDA Greenlights Arcellx’s Revitalized Clinical Trial After Partial Hold
WASHINGTON D.C. – The FDA has cleared Arcellx to resume its iMMagine-1 Phase II clinical program for its CART-ddBCMA treatment following a partial clinical hold. This treatment is for patients with relapsed or refractory multiple myeloma. The trial, which is being carried out in collaboration with Gilead’s Kite Pharma, had been put on hold in … Read more